Suppr超能文献

[原发性免疫性血小板减少症住院患儿的临床分析]

[Clinical Analysis of Hospitalized Children with Primary Immune Thrombocytopenia].

作者信息

Li Rong-Wei, Fu Rong-Feng, Chen Yun-Fei, Liu Wei, Xue Feng, Li Hui-Yuan, Zhang Lei, Yang Ren-Chi, Liu Xiao-Fan

机构信息

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Laboratory of Blood Disease Gene Therapy, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin 300020, China.

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Laboratory of Blood Disease Gene Therapy, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin 300020, China,E-mail:

出版信息

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Apr;29(2):574-580. doi: 10.19746/j.cnki.issn.1009-2137.2021.02.042.

Abstract

OBJECTIVE

To investigate the factors affecting the chronicity of childhood primary immune thrombo-cytopenia (ITP) and compare the efficiency of different first-line treatment regimens.

METHODS

Children with ITP hospitalized in our hospital from September 2013 to October 2018 were retrospectively analyzed.

RESULTS

Three hundred and one children (150 males and 151 females) were included in this study, with a median age of 8 (0.17-17) years old, and 110 (36.5%), 92 (30.6%), and 99 (32.9%) cases were grouped into newly diagnosed, persistent, and chronic ITP, respectively. The median of follow-up was 41.92 (1.07-74.03) months. At the end of the follow-up (October 2019), among the 202 newly diagnosed/persistent ITP children, 79 cases (59 newly diagnosed and 20 persistent ITP) achieved remission within 1 year after initial diagnosis, with a remission rate of 39.3%; 122 cases (50 newly diagnosed and 72 persistent ITP) developed chronic disease, with a chronicity rate of 60.7%; one case underwent splenectomy. In 99 cases with chronic ITP, 5 cases underwent splenectomy. Multivariable logistic regression analysis showed that, the insidious onset of symptoms (OR=3.754, 95%CI: 1.882-7.488, P=0.000) increased the risk of chronicity, while the positive antibody to anti-platelet membrane glycoprotein (OR=0.446, 95%CI: 0.224-0.888, P=0.021) might reduce the risk of chronicity. And no difference was found by the analysis of subtype of anti-platelet membrane glycoprotein (P=0.305). The efficacy of the first-line treatment of intravenous immunoglobulin (IVIG) alone or combined with steroid was better than that of steroid alone (P=0.028, 0.028), however, the efficiency was not significantly different between IVIG alone and combined with steroid (P=0.086).

CONCLUSION

Insidious onset of symptoms in pediatric ITP increases the risk of chronicity, while the positive titer of anti-platelet membrane glycoprotein may reduce the risk. In the first-line treatment for the newly diagnosed/persistent children. The efficacy of IVIG alone or combined with steroid is better than that of steroid alone.

摘要

目的

探讨影响儿童原发性免疫性血小板减少症(ITP)慢性化的因素,并比较不同一线治疗方案的疗效。

方法

对2013年9月至2018年10月在我院住院的ITP患儿进行回顾性分析。

结果

本研究共纳入301例患儿(男150例,女151例),中位年龄8(0.17 - 17)岁,新诊断、持续性和慢性ITP分别为110例(36.5%)、92例(30.6%)和99例(32.9%)。中位随访时间为41.92(1.07 - 74.03)个月。随访结束时(2019年10月),202例新诊断/持续性ITP患儿中,79例(新诊断59例,持续性20例)在初诊后1年内缓解,缓解率为39.3%;122例(新诊断50例,持续性72例)发展为慢性病,慢性病发生率为60.7%;1例接受脾切除术。99例慢性ITP患儿中,5例接受脾切除术。多因素logistic回归分析显示,症状隐匿起病(OR = 3.754,95%CI:1.882 - 7.488,P = 0.000)增加慢性化风险,而抗血小板膜糖蛋白抗体阳性(OR = 0.446,95%CI:0.224 - 0.888,P = 0.021)可能降低慢性化风险。抗血小板膜糖蛋白亚型分析未发现差异(P = 0.3上5)。一线治疗单独使用静脉注射免疫球蛋白(IVIG)或联合使用类固醇的疗效优于单独使用类固醇(P = 0.028,0.028),然而,单独使用IVIG与联合使用类固醇的疗效差异无统计学意义(P = 0.086)。

结论

小儿ITP症状隐匿起病增加慢性化风险,而抗血小板膜糖蛋白抗体阳性可能降低风险。对于新诊断/持续性患儿的一线治疗,单独使用IVIG或联合使用类固醇的疗效优于单独使用类固醇。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验